Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of GDC-0276 in Healthy Subjects
NCT02856152Phase 1Withdrawn
- Sponsor
- Genentech
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GDC-0276 in pain (4 arms), sponsored by Genentech. Primary endpoints: Maximum Plasma Concentration of GDC-0276 and Metabolites at 144 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration at 144 hours and 1 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
GDC-0276
03
Conditions
pain
Beyond the preview
Go deeper on NCT02856152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856152.